Leukocyte News and Research

RSS

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

22 Sep 2009

Mathematical model of an ischemic wound

Scientists expect a new mathematical model of chronic wound healing could replace intuition with clear guidance on how to test treatment strategies in tackling a major public-health problem.

22 Sep 2009

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009

Legislation grants improve research and employment initiatives in Indiana University medical campus

Indiana University School of Medicine scientists have received more than $12 million in grants funded by the federal economic stimulus legislation, funding that has bolstered both research initiatives and research employment on the medical center campus.

16 Sep 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

The most common causes worldwide include malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection. Other causes of temporary or permanent damage to the immune system include old age, medications (e.g. cortisone, cytostatic drugs), radiotherapy, stress after surgery and malignant tumors of the bone marrow and the lymph nodes.

14 Sep 2009

Master gene could lead to new ways of cancer treatments

The master gene that causes blood stem cells to turn into disease-fighting 'Natural Killer' (NK) immune cells has been identified by scientists, in a study published in Nature Immunology today. The discovery could one day help scientists boost the body's production of these frontline tumour-killing cells, creating new ways to treat cancer.

14 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

Exhibition on history of immunology to be presented at 2nd European Congress of Immunology

An exhibition entitled "The Birth of Immunology" during the 2nd European Congress of Immunology from13th to 16th September 2009 at the main foyer of the ICC in Berlin will offer insights into the fast-paced history of immunology. Immunology has promoted medical progress since the end of the 19th century like almost no other discipline.

8 Sep 2009

Microbe's multilayer defence mechanisms could treat fungal infections

Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.

8 Sep 2009

Insects can be used to test the efficiency of new drugs

Insects, such as some moths and fruit flies, react to microbial infection in the same way as mammals and so can be used to test the efficiency of new drugs, thereby reducing the need for animal testing. Dr Kevin Kavanagh from the National University of Ireland - Maynooth, presented his research findings at the Society for General Microbiology's meeting at Heriot Watt University, Edinburgh, today (8 September).

7 Sep 2009

Olympic gold medalist Shannon Miller to campaign for Stemcyte

StemCyte, Inc., one of the world's preeminent cord blood banks, today announced that Shannon Miller, a 7-time Olympic Medalist and 9-time World Medalist, has signed an endorsement partnership agreement and will appear in a series of advertising and public awareness campaigns for the company.

5 Sep 2009

New approach for understanding how drug resistance occurs in leukemia

UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.

5 Sep 2009

New protein fragments identified for anthrax vaccine development

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.

4 Sep 2009

Researchers identify new molecular switch that produces cancer cells

A team of Syracuse University researchers discovered a second molecular switch within the Mixed Lineage Leukemia protein complex that they believe could be exploited to prevent the overproduction of abnormal cells that are found in several types of cancer, including leukemia.

4 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

New ARRA-funded research on white blood cell functioning

The American Recovery and Reinvestment Act (ARRA) has provided funding for new research to learn more about how white blood cells work. Jonathan Reichner, PhD, of the department of surgery at Rhode Island Hospital has received a grant from the National Institutes of Health with funding through the American Recovery and Reinvestment Act. Reichner's hope is that the research will lead to new immune-enhancing therapies, with potential implications for improvements in both cancer treatment and controlling inflammation accompanying injury and infection.

2 Sep 2009

Psychological therapy for breast cancer patients reduces blood inflammation levels

A psychological intervention for newly diagnosed breast cancer patients with symptoms of depression not only relieves patients' depression but also lowers indicators of inflammation in the blood.

1 Sep 2009

Granulation tissue formed under gauze-based NPWT produces less scarring

At the 5th Joint Meeting of the European Tissue Repair Society and The Wound Healing Society in Limoges, France, Associate Professor Malin Malmsjo, MD, PhD of Lund University in Sweden presented never before seen ground-breaking research revealing that granulation tissue formed under gauze-based Negative Pressure Wound Therapy (NPWT) is more organized and contains fewer leukocytes than the granulation tissue formed under foam.

1 Sep 2009

Scientists discover the vulnerability of old people to cancer and skin infections

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have discovered why older people may be so vulnerable to cancer and infections in the skin. The team from UCL has shown in human volunteers that defective immunity in the skin is caused by an inability to mobilise essential defences that would otherwise recognise threats and clear them before irreparable damage is done.

28 Aug 2009